Imaging fibrosis in adults using FAPI-74 PET/CT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of Fibroblast Activating Protein (FAP) PET/CT imaging to detect fibrosis in adults with various medical conditions known to cause tissue fibrosis. Participants will receive an injection of [F-18]-FAPI-74 followed by a PET/CT scan to assess the distribution of FAP in affected organs. The study aims to gather data on the presence of fibrosis and its implications for patient prognosis, although treatment decisions will remain with the treating physicians based on clinical criteria. The study includes multiple cohorts, such as those with head and neck cancer, post-transplant lymphoproliferative disorder, and cardiac sarcoidosis.

Why it matters

Who can join: the full rules

Inclusion Criteria (by cohort)

Head and Neck Cancer Cohort:

1. Participants will be ≥ 21 years of age
2. Diagnosis of oropharyngeal squamous cell carcinoma (OPSCC)
3. Determined to be surgical candidates
4. History of known or suspected fibrosis-inducing medical condition

PTLD Cohort:

1. Participants will be ≥ 21 years of age
2. Diagnosed with microbiologically confirmed DS-pTB (culture or PCR positive)
3. History of known or suspected fibrosis-inducing medical condition.
4. Patient-reported completion of TB treatment within 2 years of enrollment.

Cardiac Sarcoidosis Cohort:

1. Participants will be ≥ 21 years of age
2. FDG PET/CT scan consistent with metabolically active cardiac sarcoidosis
3. Clinical suspicion of cardiac involvement defined as the presence of any of the following:

   1. High degree A-V nodal block
   2. Reduced left or right ventricular systolic fusion
   3. History of ventricular arrhythmias
   4. Unexplained syncope

Exploratory Cohort:

1. Participants will be ≥ 21 years of age
2. History of known or suspected fibrosis-inducing medical condition.

All Cohorts:

1\. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria (by cohort)

Head and Neck Cancer Cohort:

1\. Patient is not eligible for tissue resection

PTLD Cohort:

1. Diagnosed with TB that is resistant to rifampin per medical record review
2. History of alternative pulmonary disease per medical record review or patient self-report
3. Have been administered corticosteroids or any other systemic investigational agents within 3 months of screening per medical record review or patient self-report
4. Have symptoms or signs suggestive of active TB at the time of pre-screening per patient self-report

All Cohorts:

1. Women of childbearing potential may not be pregnant or breast-feeding. A negative pregnancy test will be required before \[F-18\]-FAPI-74injection.
2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
3. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
4. Treatment with a therapeutic agent targeting fibroblast activation protein (FAP) within 1 month prior to study enrollment.

Where it's running

• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Mark A Sellmyer, MD, PhD — University of Pennsylvania
• Study coordinator: Erin Schubert
• Email: erinschu@pennmedicine.upenn.edu
• Phone: 215-573-6569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DNP-MRSI to predict HCC treatment response

  This study tests whether DNP-MRSI imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism in liver tumors can indicate which BCLC A–C HCC lesions will respond after locoregional therapies or systemic treatment.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07807475

• Pemefolacianine imaging for lung cancer surgery

  A first-in-human dose study tests a new fluorescent imaging agent given before lung cancer surgery to see if it is safe and helps highlight tissue during thoracoscopy or robotic surgery.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07772895

• Low Dose Radiotherapy for Osteoarthritis

  This study tests whether low-dose radiotherapy can help reduce pain and improve function for adults with osteoarthritis who have not benefited from standard treatments.

  Recruiting at 2 sites Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania and 1 other locations · NCT07715188

• TumorGlow use during surgery to see sarcoma lung metastases in children

  This pediatric study tests a single 5 mg/kg dose of TumorGlow (ICG) given before surgery to help doctors see sarcoma metastases in the lungs during tumor removal.

  Recruiting Early Phase 1 Abramson Cancer Center at Penn Medicine · Phildelphia, Pennsylvania · NCT07658768

• Lifestyle and energy balance in breast cancer survivorship

  This study tests how diet, physical activity, and urinary metabolites relate to lifestyle changes in women newly diagnosed with breast cancer during treatment and survivorship.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07655934

• Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma

  This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07478848

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.